07:00 , Aug 2, 1999 |  BC Week In Review  |  Company News

Aprogenex, Vysis deal

VYSI acquired from Aprogenex 12 U.S. patents and several licensed rights covering the identification of fetal cells in maternal blood by targeting mRNA. In 1997, Aprogenex announced it would sell its assets after it could...
08:00 , Nov 24, 1997 |  BC Week In Review  |  Company News

PharmaPrint management update

PharmaPrint Inc. (PPRT), Irvine, Calif.   Business: Enabling technology   Hired: Joel Bresser as SVP, formerly president of Aprogenex Inc.  ...
07:00 , Sep 2, 1997 |  BC Week In Review  |  Company News

Aprogenex diagnostics/imaging news

APGX will sell its assets, which consist primarily of DNA probe-based test systems, after failing to secure debt or equity financing. APGX said the proceeds received from any asset sale are unlikely to cover the...
08:00 , Mar 24, 1997 |  BC Week In Review  |  Company News

LifeCell management update

LifeCell Corp. (LIFC), The Woodlands, Texas   Business: Biomaterial/Skin/Wound   Hired: J. Donald Payne, as VP, CFO and secretary; formerly VP of finance and CFO and director of Aprogenex Inc. (APG)  ...
08:00 , Mar 24, 1997 |  BC Week In Review  |  Company News

Aprogenex, Centocor deal

CNTO received worldwide rights to APG's DNA Probe in situ hybridization technology to develop an HIV diagnostic. APG received an upfront licensing fee, and is eligible for milestones and royalties. CNTO is responsible for the...
08:00 , Nov 25, 1996 |  BC Week In Review  |  Clinical News

Aprogenex regulatory update

APG received U.S. Patent No. 5,582,982 covering methods of performing flow cytometry testing, and received notice of allowance for a U.S. patent covering methods of prenatal genetic screening using maternal blood. The '982 patent involves...
07:00 , Sep 16, 1996 |  BC Week In Review  |  Company News

AmCell Corp., Aprogenex deal

APG's DNA probes will be used in AmCell's Magnetic Activated Cell Sorting technology to develop prenatal genetic testing systems. AmCell's systems separate and concentrate fetal cells from the mother's blood. The resulting diagnostic could screen...
07:00 , Sep 3, 1996 |  BC Week In Review  |  Company News

Aprogenex, BioSeparations Inc. deal

APG will exclusively supply DNA probes to BioSeparations for use in systems that screen maternal blood for circulating fetal cells in order to identify prenatal genetic disorders. BioSeparations' charge-flow separation technology concentrates fetal cells circulating...
07:00 , Apr 15, 1996 |  BC Week In Review  |  Clinical News

Aprogenex regulatory update

APG received U.S. Patent No. 5,501,952 covering analogs of chemical reporters to reduce background noise in hybridization assays. APG said probes often generate background noise when they bind with non-targeted areas. The analogs bind with...
08:00 , Nov 20, 1995 |  BC Week In Review  |  Clinical News

Aprogenex regulatory update

APG received U.S. Patent No. 5,457,024 covering a method of enriching fetal cell nucleated blood cells in a maternal sample using a leukocyte depletion device. The company acquired the technology covered in the patent through...